Wision A.I. Company Profile

Background

Founded in 2016, Wision A.I. is a Shanghai-based company specializing in artificial intelligence (AI)-assisted diagnostics for optical medical imaging. The company's mission is to develop Computer-Aided Diagnosis (CAD) algorithms and systems to enhance diagnostic accuracy and effectiveness in clinical imaging. By integrating medical knowledge into flexible and scalable models, Wision A.I. leverages cutting-edge convolutional neural networks (CNNs) and general-purpose computing to achieve stable detection efficacy in diagnostic imaging.

Key Strategic Focus

Wision A.I. focuses on developing AI-driven diagnostic tools, particularly in the field of gastrointestinal endoscopy. Their flagship product, EndoScreener, is an AI-assisted polyp detection software designed to support colonoscopy procedures. The company targets the global healthcare market, aiming to improve early detection rates of colorectal cancer through advanced AI technologies.

Financials and Funding

Wision A.I. has secured funding from investors such as Northern Light Venture Capital and MedTech Innovator. The company participated in an accelerator/incubator program in June 2019 and completed a Series A funding round in July 2018. The capital raised is intended to support the development and commercialization of their AI-assisted diagnostic products.

Pipeline Development

Wision A.I.'s primary product, EndoScreener, has achieved significant regulatory milestones:

CE-MDR Mark Approval: In November 2021, EndoScreener received the European CE Mark approval under the new Medical Devices Regulation (MDR 2017/745), marking it as the first Class II device certified under this regulation.

FDA 510(k) Clearance: In March 2022, the U.S. Food and Drug Administration granted 510(k) clearance for EndoScreener, allowing its use in the United States.

Additionally, Wision A.I. is developing a histopathology AI software aimed at localizing high-grade dysplasia in whole-slide imaging, with an FDA presubmission in progress.

Technological Platform and Innovation

Wision A.I. distinguishes itself through its proprietary AI technologies:

EndoScreener: A real-time AI-aided diagnostic tool for gastrointestinal endoscopy procedures, enhancing polyp detection during colonoscopies.

PathoCruz 3D: An automated tool for 3D reconstruction in histology, revealing tumor spatial characteristics.

Histopathology AI Software: Designed for whole-slide localization of cancerous regions in whole-slide imaging.

These technologies utilize advanced CNNs and GPU computing to achieve high sensitivity and specificity in diagnostic imaging.

Leadership Team

JingJia Liu: Co-Founder and Chief Executive Officer. Liu has been instrumental in steering the company's strategic direction and overseeing the development of its AI-assisted diagnostic tools.

Competitor Profile

Market Insights and Dynamics

The AI-assisted diagnostic imaging market is experiencing rapid growth, driven by the increasing prevalence of diseases like colorectal cancer and the demand for enhanced diagnostic accuracy. The integration of AI in medical diagnostics is transforming healthcare delivery, offering real-time analysis and improved detection rates.

Competitor Analysis

Wision A.I. faces competition from several companies in the AI-assisted diagnostic imaging sector:

Prenuvo: Provides imaging solutions with a focus on early detection of diseases.

Acarix: Develops medical devices for the treatment of coronary artery disease.

Oxymap: Specializes in technology enabling ophthalmologists to evaluate oxygen saturation in retinal blood vessels.

3DHISTECH: Offers digital pathology solutions for clinical pathologists and researchers.

Additionally, Medtronic's GI Genius, an AI system for polyp detection during colonoscopy, received FDA clearance in April 2021, presenting direct competition to EndoScreener.

Strategic Collaborations and Partnerships

In May 2022, Wision A.I. partnered with Micro-Tech Endoscopy USA, appointing them as the U.S. distributor for EndoScreener. This collaboration aims to enhance the adoption of AI-assisted polyp detection in the U.S. healthcare market.

Operational Insights

Wision A.I. differentiates itself through its focus on AI-assisted diagnostics in gastrointestinal endoscopy, particularly with EndoScreener's proven efficacy in improving adenoma detection rates. The company's strategic partnerships and regulatory approvals position it competitively in the market.